Triple
T6563408
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | fampridine |
E153840
|
entity |
| Predicate | developedBy |
P73
|
FINISHED |
| Object |
Acorda Therapeutics
Acorda Therapeutics is a biopharmaceutical company specializing in therapies for neurological disorders, particularly multiple sclerosis and other central nervous system conditions.
|
E603025
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Acorda Therapeutics | Statement: [fampridine, developedBy, Acorda Therapeutics]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Acorda Therapeutics Context triple: [fampridine, developedBy, Acorda Therapeutics]
-
A.
Juno Therapeutics
Juno Therapeutics is a biotechnology company focused on developing cutting-edge immunotherapies, particularly CAR-T cell treatments, for cancer.
-
B.
Ariad Pharmaceuticals
Ariad Pharmaceuticals was a biotechnology company focused on developing targeted therapies for cancer and other serious diseases.
-
C.
Elan Pharmaceuticals
Elan Pharmaceuticals was a biotechnology company best known for developing therapies for neurological and autoimmune diseases, including the multiple sclerosis drug Tysabri.
-
D.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
E.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Acorda Therapeutics Triple: [fampridine, developedBy, Acorda Therapeutics]
Generated description
Acorda Therapeutics is a biopharmaceutical company specializing in therapies for neurological disorders, particularly multiple sclerosis and other central nervous system conditions.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Acorda Therapeutics Target entity description: Acorda Therapeutics is a biopharmaceutical company specializing in therapies for neurological disorders, particularly multiple sclerosis and other central nervous system conditions.
-
A.
Juno Therapeutics
Juno Therapeutics is a biotechnology company focused on developing cutting-edge immunotherapies, particularly CAR-T cell treatments, for cancer.
-
B.
Ariad Pharmaceuticals
Ariad Pharmaceuticals was a biotechnology company focused on developing targeted therapies for cancer and other serious diseases.
-
C.
Elan Pharmaceuticals
Elan Pharmaceuticals was a biotechnology company best known for developing therapies for neurological and autoimmune diseases, including the multiple sclerosis drug Tysabri.
-
D.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
E.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69c6880cb35881909b763eb0125236b9 |
completed | March 27, 2026, 1:37 p.m. |
| NER | Named-entity recognition | batch_69c6ae3a40488190892d20ca0d60b937 |
completed | March 27, 2026, 4:20 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69c6d55fa1bc81908f2929e835051532 |
completed | March 27, 2026, 7:07 p.m. |
| NEDg | Description generation | batch_69c6d676e43081909bf2a9cceff0b9b3 |
completed | March 27, 2026, 7:11 p.m. |
| NED2 | Entity disambiguation (via description) | batch_69c6d843bad081909ebb887f32ea4195 |
completed | March 27, 2026, 7:19 p.m. |
Created at: March 27, 2026, 1:52 p.m.